Saint-Gobain Life Sciences Acquires France-based MS Techniques and Transluminal, Expanding its Offerings in the Minimally Invasive market
September, 14 2020
Saint-Gobain Life Sciences is broadening its medical components capabilities with the acquisition of MS Techniques and Transluminal while also establishing a European Medical Center for Excellence. The 137-person company, located in Pompey near Nancy (France), brings to Saint-Gobain years of experience in high-precision thermoplastic extrusion and design expertise for minimally invasive catheter solutions with a strong focus into the cardiovascular market. The company’s design and manufacturing capabilities will be complemented by Saint-Gobain’s material expertise, financial strength, and global presence in the medical device market. MS techniques and Transluminal will be integrated within Saint-Gobain Life Sciences’ Medical Components business unit.
At their core, both companies are very similar, and have customized, co-development models, and similar corporate cultures. Saint-Gobain is building on these synergies to bring customers the very best of both companies.
“We are looking forward to welcoming MS Techniques and Transluminal to the Saint-Gobain Medical family. Aligning with our growth strategy, they strengthen our presence in Europe, broaden our precision extrusion capabilities and catheter design expertise, helping us further expand into the interventional and minimally invasive market. ” s ays John Schmitz, General Manager for Saint-Gobain’s Medical Components and Electronics
MS Techniques and Transluminal have a strong track record of developing new catheter solutions that fit the needs of their customers. Saint-Gobain will focus on preserving, supporting, and further investing in the company’s rich culture of innovation.
“We decided to join forces with Saint-Gobain because we felt we found a true partnership and shared the same vision: to become a world-class reference in the medical device industry for delivering minimally invasive innovation. Joining a global medical organization with the size and tremendous legacy of Saint-Gobain makes it possible to carry forward what we have patiently built over the last 28 years. With more resources and the Saint-Gobain brand supporting our efforts, we pave the way for future innovation and the co-development of new medical solutions with our customers. ” says Etienne Malher, President of MS Techniques and Transluminal.
ABOUT SAINT-GOBAIN LIFE SCIENCES
Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery.
Along with material science expertise and collaborative design services, our focus on global quality and regulatory affairs allow us to be the trusted partner to organizations reaching every part of the globe. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical and pharmaceutical customers around the world. Saint-Gobain Life Sciences is part of Compagnie de Saint-Gobain.
Compagnie de Saint-Gobain designs, manufactures and distributes materials and solutions which are key ingredients in the wellbeing of each of us and the future of all. They can be found everywhere in our living places and our daily life: in buildings, transportation, infrastructure and in many industrial applications. They provide comfort, performance and safety while addressing the challenges of sustainable construction, resource efficiency and climate change. Saint-Gobain operates in 70 countries with more than 180,000 employees worldwide. The Company had € 42.6 billion in sales in 2019.